pharmaceutical daily news

Sanofi has gotten an offer from Advent International, a global investor in healthcare sector, for purchase of Zentiva, Sanofi’s European generics business for €1,9 billion.

Herantis Pharma has gotten positive results from a safety evaluation in the ongoing Phase 1 clinical study of its investigational gene therapy product Lymfactin for the treatment of secondary lymphedema.

Telix Pharmaceuticals, the specialist for radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has entered into a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or “INSERM”) and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic” (ARRONAX).

Novartis has announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, which showed that treatment with Entresto (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart failure with reduced ejection fraction (HFrEF).

Sanofi is investing €350 million for the construction of a new vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. 

Alexion has offered to buy shares in a Stockholm-based biopharmaceutical company Wilson Therapeutics, which develops novel therapies for patients with rare copper-mediated disorders.

Novartis’s acquisition of the US-based Nasdaq-listed clinical stage gene therapy company AveXis for $218 per share, for total of 8.7 billion in cash, has been approved by the boards of both companies.

Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.